Agilent Technologies Enhances Exome Sequencing for Clinical Research
March 21 2017 - 11:00AM
Business Wire
New Target Enrichment Product Delivers Deep Coverage of
Disease Relevant Content
Agilent Technologies Inc. (NYSE: A) today introduced a new
target enrichment solution for next-generation DNA sequencing.
Agilent SureSelect Clinical Research Exome V2 delivers more than
1,000 additional, disease relevant targets compared to the
company’s earlier version of the product. This is the newest
addition to Agilent’s NGS solution for human genetics which
includes a range of exome and panel designs, library preparation
reagents and unlimited custom options.
It is the only exome on the market today that delivers a
curated, annotated list of included genes, as well as evidence for
disease relevance.
Built on the proven performance of Agilent’s industry-leading
target enrichment technology, the SureSelect Clinical Research
Exome V2 provides enhanced coverage of an additional 1,099
disease-associated genes, over 75,000 splice sites of noncoding
exons, over 12,000 previously reported deep intronic variants, and
over 800 variants in promoter regions. With its larger design, the
SureSelect Clinical Research Exome V2 contains more
pathogenic/likely pathogenic variants than other exomes in the
market today. It also enables researchers to discover and identify
new disease-associated targets.
These targets were identified through an exhaustive curation
effort led by Emory University and the Children’s Hospital of
Philadelphia, both of whom were also collaborators for the first
version of the product.
“The goal of the project was to create a highly curated gene
resource and a technically optimized assay to provide a stepping
stone for standardizing interpretation of genetic variations to
fulfill the promise of genomic medicine,” said Madhuri Hegde,
adjunct professor of Human Genetics at Emory.
Avni Santani, who directs the Division of Genomic Diagnostics at
the Children’s Hospital of Philadelphia, said: “The enhanced exome
with improved coverage over medically relevant genes will improve
variant detection in these critical regions, thereby enabling more
accurate and reliable analysis of data in clinical research.”
“We are excited to be one of the first to work with the
SureSelect Clinical Research Exome V2. With the most comprehensive
design available in the market today, our study has shown it to be
an excellent tool for the efficient identification of pathogenic
variants in rare disease,” said Dr. Kirby Siemering, director of
Science and Technology at the Australian Genome Research Facility.
“We expect to move forward with the SureSelect Clinical Research
Exome V2 within AGRF’s clinical research programs.”
“Since Agilent released the first commercial exome in 2009, we
have been consistently innovating to deliver one of the
best-in-class products that enable accurate identification of novel
and disease-relevant genetic variants in constitutional samples,”
said Herman Verrelst, Agilent vice president and general manager of
the company’s Genomics Solutions Division and Clinical Applications
Division. “To that end, we are excited to partner with Emory
University and the Children’s Hospital of Philadelphia again to
offer an enhanced version of the SureSelect Clinical Research
Exome, which provides unparalleled coverage of disease-associated
gene targets.”
This new product was designed to meet the needs of clinical
research laboratories that are looking for an efficient and
cost-effective exome that can reach deep into targets that matter
most in their research.
When coupled with Agilent’s SureSelectQXT workflow, the new
exome enables researchers to create enriched libraries in just one
day—with as little as 3.5 hours of hands-on time.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in
life sciences, diagnostics and applied chemical markets, is the
premier laboratory partner for a better world. Agilent works with
customers in more than 100 countries, providing instruments,
software, services and consumables for the entire laboratory
workflow. The company generated revenues of $4.20 billion in fiscal
2016 and employs about 12,500 people worldwide. Information about
Agilent is available at www.agilent.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170321006093/en/
Agilent TechnologiesVictoria Wadsworth-Hansen,
+1-408-553-2005+45 29 33 69
80victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024